COVID-19 Distribution in Pregnancy, Drug Use Patterns and COVID-19 Medication during the Pandemic in Spain: Data from Real-World Electronic Health Records

Mota-Pérez, Mercedes; Huerta-Álvarez, Consuelo; Llorente, Ana; Cea-Soriano, Lucía

doi:10.3390/ph17020207

Cited by 1 publication

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, anticoagulant prescriptions on the wards seemed lower than reported in other investigations [13,15]. For instance, a study on COVID-19 in critically ill inpatients from Spain demonstrated that 89.1% received LMWH at hospital admission [15,17]. In our research, 77.3% of inpatients received antithrombotics at any time after the index date.…”

Section: Discussioncontrasting

confidence: 63%

“…Considering the average antithrombotic (of the heparin group) prescription rates of 26.0 and 14.6 per 1000 found in pregnant women with and without COVID-19 from Spain [17], our results demonstrated higher prescription rates for the general population. In addition, if we account for the proportion of individuals who had antithrombotic prescriptions at any time after the index date (n = 114,383, 12.9%), it was similar to the annual prevalence proportion of antithrombotic prescriptions (13.6%) reported in 2018 in the Spanish primary care population [20].…”

Section: Discussionmentioning

confidence: 51%

“…Previous investigations have described their use in ICUs or across one AC [15,16]. A recent Spanish study reported the prescription rates of antithrombotics of the heparin group in pregnant women during the pandemic [17]. However, to the best of our understanding, our study is the first nationwide real-world data analysis reporting antithrombotic use rates in the general population.…”

Section: Discussionmentioning

confidence: 89%

“…The risk of thrombosis in COVID-19 seems higher in men than women, being more frequent in younger age groups [22]. Nonetheless, it could be possible that some of the prescriptions in antithrombotic naive women were indicated as an effort to decrease the thrombotic risks associated with contraceptive therapy, postmenopausal hormone therapy, or even pregnancy [17,23,24]. However, the medical indications for antithrombotic therapy were outside the scope of this research.…”

Section: Discussionmentioning

confidence: 93%

See 3 more Smart Citations

Antithrombotic Use Patterns in COVID-19 Patients from Spain: A Real-World Data Study

Ramirez-Cervantes,

Campillo-Morales,

García-Poza

et al. 2024

JCM

Self Cite

View full text Add to dashboard Cite

Antithrombotics have been widely used to treat and prevent COVID-19-related thrombosis; however, studies on their use at population levels are limited. We aimed to describe antithrombotic use patterns during the pandemic in Spanish primary care and hospital-admitted patients with COVID-19. Methods: A real-world data study was performed. Data were obtained from BIFAP’s electronic health records. We investigated the antithrombotic prescriptions made within ±14 days after diagnosis between March 2020 and February 2022, divided their use into prior and new/naive groups, and reported their post-discharge use. Results: We included 882,540 individuals (53.4% women), of whom 78,499 were hospitalized. The median age was 44.7 (IQR 39–59). Antithrombotics were prescribed in 37,183 (4.6%) primary care subjects and 42,041 (53.6%) hospital-admitted patients, of whom 7505 (20.2%) and 20,300 (48.3%), respectively, were naive users. Prior users were older and had more comorbidities than new users. Enoxaparin was the most prescribed antithrombotic in hospitals, with higher prescription rates in new than prior users (2348.2, IQR 2390–3123.1 vs. 1378, IQR 1162–1751.6 prescriptions per 10,000 cases, p = 0.002). In primary care, acetylsalicylic acid was the most used antithrombotic, with higher use rates in prior than in naïve users. Post-discharge use occurred in 6686 (15.9%) subjects (median use = 10 days, IQR 9-30). Conclusions: Our study identified a consensus on prescribing antithrombotics in COVID-19 patients, but with low use rates in hospitals.

show abstract